LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California
01 September 2022 - 10:00PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), an innovative, molecular diagnostics
company that has commercialized the MiQLab® System for automated,
genetic testing, is pleased to announce that it has entered into a
purchase agreement with a veterinary hospital in southern
California.
Dr. Jack Regan, LexaGene’s CEO and Founder
stated, “We are pleased to close our first sale following Dr. Jane
Sykes’ webinar on the utility of using the MiQLab System for
diagnosing urinary tract infections. We will continue to build
momentum from this webinar as we demonstrate the value of the
MiQLab System in our upcoming shows.”
The Company will be exhibiting at the 28th
International Veterinary Emergency & Critical Care Symposium
(IVECCS) in San Antonio, Texas from September 7 – 11th and at the
Annual Conference of the American Animal Hospital Association
(Connexity) in Nashville, Tennessee from September 14 – 17th.
For more information about LexaGene and the
MiQLab System, please visit www.lexagene.com or follow us on
Twitter or LinkedIn.
About LexaGene Holdings
Inc. LexaGene
is a molecular diagnostics company that has commercialized the
MiQLab System for fast and easy detection of pathogens and other
molecular markers. The System is designed for on-site usage and
uses real-time PCR chemistry. Our customers include veterinary
hospitals and reference laboratories – as well as contract biologic
manufacturers. The MiQLab System delivers excellent sensitivity,
specificity, and breadth of detection.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors -- including the
availability of funds, the results of financing efforts, the
success of technology development efforts, the cost to procure
critical parts, performance of the instrument, market acceptance of
the technology, regulatory acceptance, and licensing issues -- that
could cause actual results to differ materially from the Company's
expectations as disclosed in the Company's documents filed from
time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For inquiries: 800.215.1824 | ir@lexagene.com or info@lexagene.com
Lexagene (TSXV:LXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Apr 2023 to Apr 2024